Rahul Banerjee Shared NEJM Study on Targeted Therapy of CAR+ T-Cell Lymphoma
Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared a post on X about a recent NEJM study by Adolfo Aleman et al.:
“Fighting fire with different kind of fire – excellent example of bench-to-bedside at its fastest and finest!
T-cell lymphoma 6 months after cilta-cel CAR-T in Multiple Myeloma (inserted into tumor suppressor)
CCR4 increased so mogamulizumab, and Doxil based on ex vivo screen…
Leading to remission!”
Title: Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy
Journal: NEJM
Authors: Adolfo Aleman, Oliver Van Oekelen, David T Melnekoff, Leah Grossman, Tarek H Mouhieddine, Agata Kurowski, Ivan Odak, Sidorela Reci, Shriya Desai, Shannon Meledathu, Malini P Naidu, Ravi P Shukla, Rudra P Dutta, Katerina Kappes, Kseniya Serebryakova, Hayley Jackson, Jordan Lu, Anastasia Chatikhine, Raksha Kulkarni, Zahra Moinfar, Matthew M Croken, Meenakshi Mehrotra, Brett Baskovich, Sampanna Rayamajhi, Shambavi Richard, Adriana C Rossi, Christian Salib, Jane Houldsworth, Brian D Brown, Miriam Merad, Alessandro Laganà, Patrick M Brunner, Sundar Jagannath, Joshua D Brody, Samir Parekh
More posts featuring Rahul Banerjee on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023